Quest Diagnostics is launching a new pharmacogenomics program, designed to decode patients’ DNA to predict how they will ...

Developed by Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, the lab-developed liquid biopsy test aids genomic profiling in patients with advanced non ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with cognitive decline.

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J ...

Under the terms of the agreement, Quest will offer ctDx FIRST to healthcare providers in the United States seeking a minimally invasive liquid biopsy test option as a CDx for KRAZATI.

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that detects and measures the level of PFAS.